DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

Information source: Innovative Medical
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Vitrectomy

Intervention: Nepafenac (Drug); Ketorolac LS, Bromfenac (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Innovative Medical

Official(s) and/or principal investigator(s):
Jeffrey Heier, MD, Principal Investigator, Affiliation: Ophthalmic Consultants of Boston

Summary

To compare the penetration of three different NSAIDs.

Clinical Details

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Males or females scheduled to undergo Vitrectomy surgery

- Likely to complete all study visits and able to provide informed consent

- Visual potential of 20/25 or better

Exclusion Criteria:

- Known contraindications to any study medication or ingredients

- Active ocular diseases or uncontrolled systemic disease

- Active ocular allergies

Locations and Contacts

Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, United States
Additional Information


Last updated: September 23, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017